Sign in
← Database
GLP-1 Receptor Agonist

Liraglutide

Shop · Omnichems ↗Shop · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

An established daily GLP-1 agonist with a large trial base (LEAD, SCALE, LEADER).

How it works

Liraglutide is a GLP-1 receptor agonist — the same fundamental mechanism as semaglutide, just a daily rather than weekly version. It mimics the gut hormone GLP-1 to influence insulin, appetite, and digestion.

On the receptor it does the familiar GLP-1 work: glucose-dependent insulin release, glucagon suppression, increased satiety via brain appetite centers, and slowed gastric emptying. The practical difference is durability — liraglutide's single fatty-acid tail binds albumin less tightly, so it clears in about 13 hours and needs daily injection.

It has a long, well-characterized record (LEAD, SCALE, LEADER) and is approved for type 2 diabetes and weight management. Side effects are the usual GLP-1 gastrointestinal ones, and it shares the class C-cell precaution.

Mechanism · Detailed Analysis
Molecular targetGLP-1 receptor agonist — the same target and cascade as semaglutide.
Signaling & downstream effectsGlucose-dependent insulin secretion, glucagon suppression, central satiety, and delayed gastric emptying.
PharmacokineticsA single C16 palmitoyl acylation gives a ~13 h half-life and once-daily dosing — less albumin avidity than semaglutide.
CaveatsGLP-1 class effects (GI events, gallbladder, C-cell warning).
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.